The fresh blow to Roche’s hopes in a closely watched class of cancer immunotherapies cast a long shadow across the crowded field on May 11, but the latest setback is not the end of the road for these oncology treatments, analysts say.
https://www.pharmalive.com/wp-content/uploads/2022/05/New-class-of-cancer-drugs-down-not-out-after-Roche-trial-setback-–-analysts-Reuters-5-11-22.jpg503960Reuters Healthhttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngReuters Health2022-05-11 14:48:532022-05-11 15:58:04New class of cancer drugs down, not out, after Roche trial setback – analysts